Skip to main content
Back to feed
HealthReportedMedium
5.2

Egetis wins FDA approval for MCT8 deficiency drug; CEO disputes analyst skepticism

Egetis Therapeutics received FDA approval for its treatment of MCT8 deficiency, opening the US market. Analyst Pareto views the approval as expected and questions commercial potential, but CEO Nicklas Westerholm disagrees, signaling confidence in the drug's prospects. The approval marks a regulatory milestone for the rare disease therapy, though market uptake remains uncertain.

Dagens Industri5 days agoUS, SECredibility 27%View source

Score Breakdown

Mosaic Score5.2
Model confidence0.9
Significance0.5
Source credibility0.3

Intelligence Tags

#fda-approval#rare-disease#egetis-therapeutics#mct8-deficiency#pharmaceuticals

Entities

countrycountry
Source

Related signals

8 found